Abstract
Constitutive activation of the KRAS oncogene in human malignancies is associated with aggressive tumor growth and poor prognosis. Similar to other oncogenes, KRAS acts in a cell-intrinsic manner to affect tumor growth or survival. However, we describe here a different, cell-extrinsic mechanism through which mutant KRAS contributes to tumor development. Tumor cells carrying mutated KRAS induced highly suppressive T cells, and silencing KRAS reversed this effect. Overexpression of the mutant KRAS(G12V)gene in wild-type KRAS tumor cells led to regulatory T-cell (Treg) induction. We also demonstrate that mutant KRAS induces the secretion of IL10 and transforming growth factor-β1 (both required for Treg induction) by tumor cells through the activation of the MEK-ERK-AP1 pathway. Finally, we report that inhibition of KRAS reduces the infiltration of Tregs in KRAS-driven lung tumorigenesis even before tumor formation. This cell-extrinsic mechanism allows tumor cells harboring a mutant KRAS oncogene to escape immune recognition. Thus, an oncogene can promote tumor progression independent of its transforming activity by increasing the number and function of Tregs. This has a significant clinical potential, in which targeting KRAS and its downstream signaling pathways could be used as powerful immune modulators in cancer immunotherapy.
Original language | English |
---|---|
Pages (from-to) | 354-365 |
Number of pages | 12 |
Journal | Cancer immunology research |
Volume | 4 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2016 |
Keywords
- Research Support, N.I.H., Intramural
Fingerprint Dive into the research topics of 'Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells'. Together they form a unique fingerprint.
Profiles
-
Rasha Abu Eid
- School of Medicine, Medical Sciences & Nutrition, Dental Education - Senior Lecturer
- Clinical Medicine
- Institute of Medical Sciences
Person: Academic